Nordic Nanovector ASA announces its second quarter and first half 2018 results on Wednesday, 22 August 2018.
OSLO, Norway, 8 August, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces its second quarter and first half 2018 results on Wednesday, 22 August 2018.
Second Quarter and First Half 2018 Results Presentation and Webcast
A presentation by Nordic Nanovector’s senior management team in English will take place at 8:30 am CEST on 22 August at:
Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo
Meeting Room: AKER
The presentation will be recorded as a webcast and will be available at www.nordicnanovector.com in the section: Investors & Media
The results report and the presentation will be available at www.nordicnanovector.com in the section: Investors & Media/Reports and Presentations/Interim Reports/2018 from 7:00 am CEST the same day.
Results presentation in Norwegian
A separate presentation of the results in Norwegian, to be hosted by Nordic Nanovector’s CFO, and its VP IR & Corporate Communications, will take place on Thursday, 23 August 2018 at 8:30 am CEST at:
Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo
Meeting Room: VIPPETANGEN
To attend this meeting please email - ir@nordicnanovector.com
The presentation will NOT be recorded as a webcast
For further information, please contact:
IR enquiries
Malene Brondberg
VP Investor Relations and Corporate Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-asa-invitation-to-second-quarter-and-first-half-2018-results-presentation-and-webcast-300693801.html
SOURCE Nordic Nanovector
Company Codes: Dusseldorf:8NN, LSE:0R6Y, Oslo:NANO, Stockholm:NANOO, Frankfurt:8NN, Stuttgart:8NN
